In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Nearly 200 participants from 50 Unani Academia and Council participated
Subscribe To Our Newsletter & Stay Updated
